EvoPAR-Breast01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative, BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Condition: Breast Cancer

Sponsor: AstraZeneca

Full Title
Protocol D9722C00001: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer

Study Treatment
Study participant treatment will be randomized 2:2:1 between the following 3 treatment arms:

• Arm 1: PARP1 inhibitor saruparib in combination with next generation selective estrogen receptor degrader camizestrant
• Arm 2: Physician's choice CDK4/6 inhibitor in combination with standard endocrine therapy
• Arm 3: Physician's choice CDK4/6 inhibitor in combination with camizestrant

Eligibility/Info
Advanced or metastatic hormone receptor positive, HER2 negative breast cancer with a loss of function mutation in BRCA1, BRCA2, or PALB2. Participants must not have been treated with systemic anti-cancer therapy in the advanced/metastatic setting.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage